The Wolverhampton Assessment Tool, a Tool for Patient-reported Wellbeing in the Context of Prostate Cancer (WATapp)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04851639|
Recruitment Status : Recruiting
First Posted : April 20, 2021
Last Update Posted : April 20, 2021
This is a study of the Wolverhampton Assessment Tool (WATapp), a five-item questionnaire for patients with advanced or metastatic prostate cancer to say how they feel normally in terms of pain, urinary frequency, eating, and tiredness. It is widely recognised that patient-reported outcomes give a measure of overall effect of clinicians' actions on patients and that they can be used to guide the management of the patient's condition.
WATapp is designed to reduce the need for the patient to attend hospital so much for routine follow-up consultations (an important aspect in light of COVID-19), to give the man some sense of agency and control and to inform his clinician of just he feels he is coping with his treatment. Now we want to find out just how the results from WATapp correspond to, for example, changes in PSA, testosterone or other blood results which are routinely measured; and to find out how patients and clinicians feel about using WATapp.
Men with advanced or metastatic prostate cancer will be eligible to take part in the study and participation is in addition to whatever treatment they are on. Clinicians who choose to offer WATapp to their patients will also be invited to take part and they will be asked to share with the researchers anonymised, linked patient data and scores from WATapp.
|Condition or disease||Intervention/treatment||Phase|
|Advanced Prostate Carcinoma||Other: Wolverhampton Assessment Tool||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||any patient with advanced or metastatic prostate cancer|
|Masking:||None (Open Label)|
|Official Title:||The Wolverhampton Assessment Tool, a Step Towards Remote Monitoring of Patient-reported Wellbeing in the Context of Prostate Cancer|
|Actual Study Start Date :||September 1, 2020|
|Estimated Primary Completion Date :||September 30, 2024|
|Estimated Study Completion Date :||March 30, 2025|
Experimental: Proof of principle
Proof of principle of the efficacy and utility of the WATapp
Other: Wolverhampton Assessment Tool
a proxy means for assessing whether clinician intervention is required and to assess patient's lived quality of life
- WATapp as a proxy for patients' clinical status [ Time Frame: up to 48 months ]The correlation between the patient's responses to WATapp and their clinical status as measured by routine bloods and clinician assessment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04851639
|Contact: David Matheson, PhDfirstname.lastname@example.org|
|Royal Wolverhampton Hospital NHS Trust||Recruiting|
|Wolverhampton, United Kingdom, WV10 0QP|
|Contact: Ian Sayers, MBBS 07789935567 email@example.com|
|Principal Investigator:||David Matheson, PhD||University of Wolverhampton|